Your trusted source for investing success

Tag: License Agreement

Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis

Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into a license agreement with Polyphor Ltd. for POL6014, a clinical stage selective inhibitor of human neutrophil elastase with the potential to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases such as non-cystic fibrosis bronchiectasis (NCFB), alpha-1 antitrypsin deficiency (AATD)

Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

Pieris Pharmaceuticals (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seattle Genetics (NASDAQ: SGEN), a global biotechnology company developing innovative, targeted therapies for cancer, today announced they have entered into a collaboration and license agreement with the goal of

VBL Therapeutics Receives Milestone Payment

VBL Therapeutics (Nasdaq:VBLT) today announces that it has received a milestone payment from NanoCarrier, (TSE Mothers:4571) in relation to the license agreement for the development, commercialization, and supply of ofranergene obadenovec in Japan.

As quoted in the press release:
“We are excited about reaching this important milestone with NanoCarrier, and for the continuing development

Elite Pharmaceuticals and SunGen Pharma File ANDA

Elite Pharmaceuticals (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed an Abbreviated New Drug Application with the US Food and Drug Administration (FDA) for a generic version of an immediate release CNS stimulant.

As quoted in the press release:
“The filing of

3tl Technologies Signs Seven Licensing Agreements

3tl Technologies (TSXV:TTM) has announced it has signed seven licensing agreements and revenue growth of nearly 80 percent.

As quoted in the press release:

Approximately 60% of the revenues from the seven license agreements will be recognized in 2018. 3tl is positioned for another year of strong revenue growth in 2018, with

Falco Announces Positive Feasibility Study Results on Horne 5 Gold Project

Falco Announces Positive Feasibility Study Results on Horne 5 Gold Project

-Top Quartile Project at All-In Sustaining Costs of US$399/oz Au, net of By-Product Credits
-All-In Cost (CAPEX plus OPEX) at US$643/oz Au
-Annual Payable Gold Production of 219,000 Ounces for 15 Years
-After-Tax IRR of 15.3%
Falco Resources Ltd. (“Falco” or the “Company”)(TSXV:FPC) is pleased to announce the results of a feasibility study (the “Feasibility Study”

BlackBerry and BLU Products Enter into Patent License Agreement

BlackBerry Limited (NASDAQ:BBRY; TSX:BB) and BLU Products have announced that they have entered into a patent license agreement.

As quoted in the press release:
This will result in settlement of all existing patent litigation between the two companies and withdrawal of pending actions in the United States. The financial structure of the

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
Big News RoundUp: Isodiol International Signs Definitive Agreement to Acquire 100% of Canadian National Pharma Group, Clinical Study on Phivida’s Nano-CBD™ at the University of Nottingham (UK) in Collaboration with Artelo Biosciences, Inc.,ChroMedX CEO Lahav Gil Assembles Task-Force to Explore Feasibility and Applications of Automated Ultrafiltration Technology